Government Raises Price Cap for Key Cancer Drugs by 50% Amid Supply Shortages

As per Reuters reports, India's drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), has approved a 50% increase in the ceiling prices of two platinum-based cancer drugs. 

The decision was taken under special provisions after concerns emerged over supply disruptions and shortages of these medicines across the country. 

NPPA Raises Ceiling Prices for Cancer Drugs 

According to a government notification dated June 11, the ceiling price of cisplatin has been increased to ₹10.89 per ml from ₹7.26 per ml. 

Similarly, the ceiling price of carboplatin has been raised to ₹90.74 per ml from ₹60.49 per ml, excluding applicable taxes. 

Move Aims to Address Drug Shortages 

The regulator stated that shortages and supply disruptions of cisplatin and carboplatin formulations had raised concerns regarding the availability of essential oncology medicines. 

Both drugs are widely used in the treatment of cancers such as ovarian, lung, and bladder cancer. 

Rising Platinum Costs Impact Production 

Industry participants have attributed supply challenges to a sharp increase in platinum prices, a key raw material used in manufacturing these drugs. 

India relies heavily on imported platinum, and supply constraints from major producing regions have contributed to higher input costs. 

Several Pharmaceutical Companies Manufacture the Drugs 

The formulations are manufactured by multiple pharmaceutical companies, including Cipla, Intas Pharmaceuticals, Naprod Life Sciences, and Venus Remedies. 

The price revision is expected to provide relief to manufacturers facing increased production costs. 

Revision To Be Reviewed After Six Months 

The NPPA stated that the increase is a one-time revision and will be subject to review after 6 months. The measure was approved in public interest to ensure uninterrupted availability of critical cancer medicines. 

Read More: Government Reduces Gold Base Import Price by $80 per 10 gm to $1,343 per 10 gm! 

Conclusion 

The revised ceiling prices for cisplatin and carboplatin have been introduced to address supply disruptions and improve the availability of essential oncology drugs. The one-time increase will remain subject to review after six months. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.